EcoDrugPlus

Carbonic Anhydrase 1-Like

Ensembl ID : ENSBTAG00000051812
Gene Symbol: LOC100847874
4 Cross references
287 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSBTAG00000019390
Gene Symbol: CA12
2 Enzyme and pathways 5 Cross references
227 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSBTAG00000001000
Gene Symbol: CA13
2 Enzyme and pathways 5 Cross references
303 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSBTAG00000021481
Gene Symbol: CA14
2 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Carbonic Anhydrase 3

Ensembl ID : ENSBTAG00000015214
Gene Symbol: CA3
2 Enzyme and pathways 5 Cross references
322 Possible Orthologues:

Carbonic Anhydrase 4

Ensembl ID : ENSBTAG00000017969
Gene Symbol: CA4
6 Enzyme and pathways 5 Cross references
345 Possible Orthologues:

Carbonic Anhydrase 5a

Ensembl ID : ENSBTAG00000010151
Gene Symbol: CA5A
2 Enzyme and pathways 5 Cross references
182 Possible Orthologues:

Carbonic Anhydrase 5b

Ensembl ID : ENSBTAG00000020418
Gene Symbol: CA5B
2 Enzyme and pathways 5 Cross references
235 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSBTAG00000009515
Gene Symbol: CA6
2 Enzyme and pathways 5 Cross references
239 Possible Orthologues:

Carbonic Anhydrase 7

Ensembl ID : ENSBTAG00000020889
Gene Symbol: CA7
2 Enzyme and pathways 5 Cross references
233 Possible Orthologues:

Carbonic Anhydrase 9

Ensembl ID : ENSBTAG00000011420
Gene Symbol: CA9
2 Enzyme and pathways 5 Cross references
292 Possible Orthologues:

Carbonic Anhydrase I

Ensembl ID : ENSBTAG00000032236
Gene Symbol: CA1
6 Enzyme and pathways 4 Cross references
287 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).